Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC-74020
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
SC-74020 is an experimental small molecule belonging to the benzanilide class of organic compounds. Its chemical formula is C29H42N4O6S, and it has a molecular weight of approximately 574.7 g/mol. The compound has been studied for its interaction with the catalytic domain of human matrix metalloproteinase 2 (hMMP-2), suggesting potential as an inhibitor or modulator of this enzyme, which plays a role in cancer metastasis and tissue remodeling. However, there are no approved indications or advanced clinical trials reported for this compound[1][2][5].
- Other names
- N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl][2-(morpholin-4-yl)ethyl]sulfamoyl}phenyl)-4-pentylbenzamide
02
Targets
MMP2 (Matrix metalloproteinase-2)
Beyond the preview
Go deeper on SC-74020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SC-74020.